Pancreatic mucinous cystadenoma with serum CA 19–9 over 1,000,000 U/mL: a case report and review of the literature
© Costa et al.; licensee BioMed Central. 2015
Received: 6 October 2014
Accepted: 21 January 2015
Published: 25 February 2015
The diagnosis of pancreatic cystic neoplasms has become more accurate recently. In some cases, however, doubt remains regarding the lesion’s malignant potential. CA 19–9 has long been identified as a reliable biomarker in differentiating pancreatic benign and malignant lesions, especially in non-jaundiced patients.
Case report and discussion
We report a case of a young female who presented with a mucinous lesion in the tail of the pancreas and a serum CA 19–9 over 1,000,000 U/mL. She was taken to surgery and had a distal pancreatectomy and splenectomy. Pathology reports showed only a mucinous cystadenoma. After 1 year of follow-up, her serum CA 19–9 was normal. Following that, the work-up in these lesions, the role of the biomarker in pancreatic adenocarcinoma and in the differentiation between benign and malignant lesions is discussed.
Pancreatic cystic neoplasms (PCNs) still constitute a challenge in everyday clinical practice. Current imaging diagnostic methods, increasingly more sophisticated and associated with an ever-increasing spectrum of serum biomarkers or cystic content analysis, are still not able to differentiate reliably enough the benign lesions, amenable to follow-up, from those malignant or premalignant lesions that require surgical treatment.
Upper gastrointestinal (UGI) endoscopy did not show any extrinsic compression or gastric/duodenal wall invasion.
No endoscopic ultrasound was indicated, since the main diagnostic hypothesis was a mucinous lesion with malignant transformation, and its treatment included surgery, provided that no metastatic disease was found.
Clinical stabilization and preoperative evaluation was performed, with no additional significant findings. The patient was the taken to the operating room. At first, she underwent a diagnostic laparoscopy, with no signs of peritoneal and liver metastasis. Laparotomy was then performed, and a distal pancreatectomy with splenectomy was conducted. The patient had an uneventful postoperative outcome and was discharged on the fifth postoperative day.
The final pathology report provided the diagnosis of a mucinous cystic neoplasm with moderate dysplasia and no signs of invasion.
Its macroscopic exam described a 6-cm well-delineated cystic tumor surrounded by a thick, fibrotic capsule. In its composition, multiple cysts with trabecular and thickened septa were observed. The cysts contents were mucoid and showed no areas of solid tumor. Degenerative changes, including hemorrhage and macrocystic degeneration were seen in focal areas.
On the 40th postoperative day, the patient had an outpatient visit, reporting no symptoms and without any change in blood glucose levels. The CA 19–9 serum concentration at that time was 688 U/mL. Additionally, the patient brought a complete abdominal ultrasonography showing only postoperative changes.
After 5 months, the patient remained without complaints and her CA 19–9 serum concentration was still above normal (56 U/mL).
In a late postoperative visit, 1 year after surgery, her CA 19–9 serum concentration had returned to normal levels (35.2 U/mL). No abnormal events have been recorded since, with 3 years of follow-up.
A controversy has been observed regarding the appropriate indication for surgery in some pancreatic tumors, with some authors identifying up to 30% of unnecessary resections . Differentiation of pancreatic tumors between benign and malignant, whether cystic, solid, or mixed lesions, is essential for the best course of treatment. PCNs remain a perfect example of tumors that present in a variable way and in which surgical treatment should be tailored. Their incidence has been increasing through the years, albeit with a proportional reduction in the finding of malignant lesions . Therefore, the knowledge of the varieties of PCNs, as well as the correct differentiation between inflammatory or serous lesions, which present no potential for malignant transformation and those of mucinous lesions which are premalignant , is mandatory for choosing the appropriate therapeutic approach.
The widespread use of imaging tools in differentiating these tumors has provided safe diagnosis for typical lesions; however, many cystic tumors show intermediate characteristics between benign and malignant ones. Even with the use of modern methods of diagnostic imaging, such as contrast-enhanced ultrasonography and endoscopic ultrasonography associated with fine needle aspiration (FNA), which are also important in this differentiation [4,5], the decision between expectant and surgical course of treatment will also involve factors beyond imaging characteristics, such as serum biomarker concentrations, patient status, and the presence or absence of symptoms [6,7].
An ‘ideal’ tumor biomarker is highly sensitive in identifying disease in an asymptomatic population. CA 19–9, a serum carbohydrate antigen produced by exocrine epithelial cells, was first described more than three decades ago . It is the only blood test approved by the Food and Drug Administration (FDA) for pancreatic adenocarcinoma. CA 19–9 has demonstrated specificity of approximately 85% and sensitivity of 90% [9,10], and its prognostic value for survival is more associated with high postoperative dosage .
In evaluating benign and malignant intraductal papillary mucinous neoplasms (IPMNs), CA 19–9 has a role in the differentiation invasive and benign lesions. In a study with 142 patients, 80% of those with invasive IPMNs had CA 19–9 over 37 U/ml versus only 18% of those with benign lesions. The specificity was 85.9% and accuracy 81.7% . A cancer center series of 287 resected patients with the diagnosis of IPMN reported preoperative carcinoembryonic antigen (CEA) and CA 19–9 serum concentrations in 112 patients. Among them, one biomarker was elevated in 23 individuals (20.5%), of which 16 (69%) had invasive tumor in the final anatomopathological result (P < 0.01). The authors advocated that Sendai criteria-negative patients who present elevated CA 19–9 be considered for surgery .
Two other common cystic neoplasms, serous and mucinous cystoadenomas, have a different pattern of CA 19–9 concentrations. In an American study with 114 patients, CA 19–9 was rarely elevated in serous lesions, but was associated with increases of up to sixfold in mucinous ones, with the presence of symptoms being the most sensitive criterion for malignancy. The cut-off value used was 35 mg/dL .
In patients with resectable ductal adenocarcinoma, the increase of CA 19–9 has had an impact on staging and survival. In a large series of 424 patients, tumors that were larger and had lymph node metastasis were associated with a median CA 19–9 over 160 U/mL. Also, individuals with CA 19–9 over 1,000 U/mL had median survival time of only 1 year . Similar findings were observed in a British series with 109 subjects, but a different cut-off value was identified. Patients with a CA 19–9 level over 150 kU/L had worse overall survival, poorly differentiated tumors, and more commonly had a resection with positive margins . For patients undergoing neoadjuvant chemotherapy prior to resection, it was demonstrated that those with serum concentrations of CA 19–9 greater than 1,167 U/mL had a survival rate around 8 months .
It must be reminded that some patients, while having invasive neoplasm, do not have an increase in CA 19–9, as 5% to 7% of the population has the Lewis blood group phenotype Le(a-b-) that does not synthesize the antigen detected by the antibody CA 19–9 .
Further tools have been investigated in order to earlier detect cysts that tend to progress. Genetic analysis of their content constitutes a horizon of particular interest. The concentrations of the CEA biomarker in the cyst can help differentiate between serous and mucinous lesions, but cannot, however, infer malignancy . Detection of K-RAS gene mutation and loss of amplitude in allele expression in cyst fluid confer specificity up to 96% for the diagnosis of mucinous malignant lesions, but with specificity as low as 37% .
The PAM4 marker, an antigen produced by tumor cells, shows a sensitivity of 76% with a specificity of 96% in the diagnosis of pancreatic adenocarcinoma, including in the early stages of onset. The association of CA 19–9 concentrations to PAM4 conferred 84% specificity in diagnosis, regardless of serum bilirubin concentrations .
One scenario in which CA 19–9 results must be interpreted with caution is in jaundiced patients. Those who present with benign pathologies of the biliopancreatic tract coursing with jaundice have CA 19–9 concentrations above 37 U/mL at a frequency of up to 64.7% versus 7.3% in non-jaundiced patients, showing the limited potential of CA 19–9 concentrations in the differential diagnosis between benign and malignant conditions in jaundiced individuals .
In the case in question, no focal point of invasion was identified and the patient remained anicteric throughout the course of the disease. The presence or absence of dysplasia, and the degree thereof, has shown no correlation with the serum concentrations of biomarkers. This just confirms the authors’ findings that in spite of the vast evolution of diagnostic methods, whether originating from imaging or the laboratory, the correlation between the preoperative diagnosis and the postoperative histological diagnosis of the surgical specimen still revolves around 78.4% .
In the current report, a case is presented in which a young female patient has a single pancreatic cystic lesion in the pancreatic tail and also preoperative serum marker of 1,000,000 U/ml, whose pathology report identified just a mucinous cystoadenoma, with no invasive tumor. This further demonstrates that biomarkers should be used as a diagnostic and staging aid and should not be used for screening and/or defining treatment course.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors would like to acknowledge the participation of Todd Price, an English-native speaker, who helped with manuscript language review.
- Jesipowicz J, Piłat J, Jesipowicz M, Matras P, Rudzki S. Late detection, progress and results of treatment of pancreatic cancer. Wspolczesna Onkol. 2000;4:76–9.Google Scholar
- Valsangkar NP, Morales-Oyarvide V, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, et al. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012;152:S4–12.View ArticlePubMed CentralPubMedGoogle Scholar
- Fasanella KE, McGrath K. Cystic lesions and intraductal neoplasms of the pancreas. Best Pract Res Clin Gastroenterol. 2009;23:35–48.View ArticlePubMedGoogle Scholar
- Kwon RS. Advances in the diagnosis of cystic neoplasms of the pancreas. Curr Opin Gastroenterol. 2012;28:494–500.View ArticlePubMedGoogle Scholar
- Roggin KK, Chennat J, Oto A, Noffsinger A, Briggs A, Matthews JB. Pancreatic cystic neoplasm. Curr Probl Surg. 2010;47:459–510.View ArticlePubMedGoogle Scholar
- Allen PJ, D’Angelica M, Gonen M, Jaques DP, Coit DG, Jarnagin WR, et al. A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg. 2006;244:572–82.PubMed CentralPubMedGoogle Scholar
- Katz MH, Mortenson MM, Wang H, Hwang R, Tamm EP, Staerkel G, et al. Diagnosis and management of cystic neoplasms of the pancreas: an evidence based approach. J Am Coll Surg. 2008;207:106–20.View ArticlePubMedGoogle Scholar
- Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350–5.PubMedGoogle Scholar
- Murakami Y, Uemura K, Ohge H, Hayashidani Y, Sudo T, Suedo T. Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery. 2006;140:448–53.View ArticlePubMedGoogle Scholar
- Rudnicki J, Agrawal AK, Grzebieniak Z, Zukrowski P, Zysko D, Jelen M, et al. Prognostic value of CA 19–9 level in resectable pancreatic adenocarcinoma. Folia Histochem Cytobiol. 2010;48:249–61.PubMedGoogle Scholar
- Joergensen MT, Brunner N. Schaffalitzky De Muckadell OB. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res. 2010;2:587–92.Google Scholar
- Fritz S, Hackert T, Hinz U, Hartwig W, Büchler MW, Wer-ner J. Role of serum carbohydrate antigen 19–9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg. 2011;98:104–10.View ArticlePubMedGoogle Scholar
- Fritz S, Klauss M, Bergmann F, Hackert T, Hartwig W, Strobel O, et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg. 2012;256:313–20.View ArticlePubMedGoogle Scholar
- Jones NB, Hatzaras I, George N, Muscarella P, Ellison EC, Melvin WS, et al. Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancreas: a single institution experience. HPB. 2009;11:664–70.View ArticlePubMed CentralPubMedGoogle Scholar
- Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897–902.View ArticlePubMedGoogle Scholar
- Smith RA, Bosonnet L, Ghaneh P, Raraty M, Sutton R, Campbell F, et al. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg. 2008;25:226–32.View ArticlePubMedGoogle Scholar
- Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, et al. Carbohydrate antigen 19–9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 2009;115:2630–9.View ArticlePubMedGoogle Scholar
- Koprowski H, Brockhaus M, Blaszczyk M, Magnani J, Steplewski Z, Ginsburg V. Lewis blood-type may affect the incidence of gastrointestinal cancer. Lancet. 1982;1:1332–3.View ArticlePubMedGoogle Scholar
- Sarr MG, Schnelldorfer T, Lombardo KMR, Chari ST. Advances in our understanding of cystic neoplasms of the pancreas. Am J Surg. 2007;194:S100–3.View ArticleGoogle Scholar
- God DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, et al. PAM4 enzyme immunoassay alone and in combination with CA 19–9 for the detection of pancreatic adenocarcinoma. Cancer. 2013;119:522–8.View ArticleGoogle Scholar
- Duraker N, Hot S, Polat Y, Höbek A, Gençler N, Urhan N. CEA, CA 19–9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95:142–7.View ArticlePubMedGoogle Scholar
- Salvia R, Malleo G, Marchegiani G, Pennachino S, Paiella S, Paini M, et al. Pancreatic resections for cystic neoplasms: from the surgeon’s presumption to the pathologist’s reality. Surgery. 2012;152:S135–42.View ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.